HomeCompareCTXRW vs SPHD

CTXRW vs SPHD: Dividend Comparison 2026

CTXRW yields 1387.93% · SPHD yields 4.33%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CTXRW wins by $346908156.07M in total portfolio value
10 years
CTXRW
CTXRW
● Live price
1387.93%
Share price
$0.14
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$346908156.10M
Annual income
$303,843,436,712,884.44
Full CTXRW calculator →
SPHD
SPHD
● Live price
4.33%
Share price
$49.34
Annual div
$2.14
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$571.32
Full SPHD calculator →

Portfolio growth — CTXRW vs SPHD

📍 CTXRW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCTXRWSPHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CTXRW + SPHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CTXRW pays
SPHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CTXRW
Annual income on $10K today (after 15% tax)
$117,973.63/yr
After 10yr DRIP, annual income (after tax)
$258,266,921,205,951.75/yr
SPHD
Annual income on $10K today (after 15% tax)
$367.92/yr
After 10yr DRIP, annual income (after tax)
$485.62/yr
At 15% tax rate, CTXRW beats the other by $258,266,921,205,466.12/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CTXRW + SPHD for your $10,000?

CTXRW: 50%SPHD: 50%
100% SPHD50/50100% CTXRW
Portfolio after 10yr
$173454078.06M
Annual income
$151,921,718,356,727.88/yr
Blended yield
87.59%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CTXRW buys
0
SPHD buys
0
No recent congressional trades found for CTXRW or SPHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCTXRWSPHD
Forward yield1387.93%4.33%
Annual dividend / share$2.00$2.14
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$346908156.10M$26.5K
Annual income after 10y$303,843,436,712,884.44$571.32
Total dividends collected$343747776.19M$5.1K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: CTXRW vs SPHD ($10,000, DRIP)

YearCTXRW PortfolioCTXRW Income/yrSPHD PortfolioSPHD Income/yrGap
1← crossover$149,493$138,792.51$11,133$432.85+$138.4KCTXRW
2$2,099,063$1,939,106.48$12,363$450.36+$2.09MCTXRW
3$27,692,262$25,446,263.94$13,695$467.39+$27.68MCTXRW
4$343,373,046$313,742,325.46$15,138$483.90+$343.36MCTXRW
5$4,003,185,043$3,635,775,884.26$16,697$499.88+$4003.17MCTXRW
6$43,897,781,482$39,614,373,485.65$18,382$515.31+$43897.76MCTXRW
7$452,951,824,425$405,981,198,239.62$20,198$530.17+$452951.80MCTXRW
8$4,399,656,810,870$3,914,998,358,735.43$22,157$544.46+$4399656.79MCTXRW
9$40,247,401,294,059$35,539,768,506,427.31$24,266$558.18+$40247401.27MCTXRW
10$346,908,156,097,527$303,843,436,712,884.44$26,536$571.32+$346908156.07MCTXRW

CTXRW vs SPHD: Complete Analysis 2026

CTXRWStock

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Full CTXRW Calculator →

SPHDETF

The Invesco S&P 500 High Dividend Low Volatility ETF (Fund) is based on the S&P 500 Low Volatility High Dividend Index (Index). The Fund will invest at least 90% of its total assets in common stocks that comprise the Index. Standard & Poor's compiles, maintains and calculates the Index, which is composed of 50 securities traded on the S&P 500 Index that historically have provided high dividend yields and low volatility. The Fund and the Index are rebalanced and reconstituted semi-annually, in January and July.

Full SPHD Calculator →
📬

Get this CTXRW vs SPHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CTXRW vs SCHDCTXRW vs JEPICTXRW vs OCTXRW vs KOCTXRW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.